Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults With Chronic Illness and Their Parents
Sponsor study identifier
Secondary identifiers
observational
252
1 country
1
Study Start
August 6, 2012
Actual (reported)Primary Completion
June 28, 2023
Actual (reported)Study Completion
June 28, 2023
Actual (reported)Background: \- Assessing pain levels is important to improve treatments for different illnesses. Most pain rating scales are used to determine pain levels in adults. Pain is also a common symptom among children who have cancer. Those who have genetic conditions that may lead to cancer may also have pain symptoms. However, the pain scales used for adults have not been fully tested in children and young adults. As a result, they may not be as accurate. Researchers want to test pain rating scales in children and young adults who have cancer and genetic conditions that can lead to cancer. Objectives: \- To study the effectiveness of pain rating scales given to children and adults with Sickle Cell Disease (SCD),cancer, and related genetic conditions. Eligibility: \- Adults 18 and 34 years of age and older who have SCD, cancer, or other genetic conditions that can lead to cancer. Design:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 28, 2023
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 11, 2012
Actual (reported)July 13, 2012
Actual (reported)August 6, 2012
Actual (reported)June 28, 2023
Actual (reported)June 28, 2023
Actual (reported)Feasability
To validate the Pain Interference Index and the Pain Rating Scale by comparison with previously validated measures
One time
Validation
One month
Feasability
One time
Feasability
One time
Adults patients with cancer or neurofibromatosis 1 (NF1)
Adults with sickle cell disease (SCD)
Children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
Parents of children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
Children, adolescents, and young adults ages 6 to 25 years with chronic pain related to cancer, Neurofibromas type 1 (NF1), genetic tumor predisposition syndromes (GTPS), a solid tumor (including but not limited to sarcoma, neuroblastoma, or melanoma), or leukemia and their parent(s) or guardians. (COMPLETED) Adults \>/= 18 years of age with cancer, NF1, Sickle Cell Disease (SCD)
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Fayers PM, Hjermstad MJ, Klepstad P, Loge JH, Caraceni A, Hanks GW, Borchgrevink P, Kaasa S; European Palliative Care Research Collaborative (EPCRC). The dimensionality of pain: palliative care and chronic pain patients differ in their reports of pain intensity and pain interference. Pain. 2011 Jul;152(7):1608-1620. doi: 10.1016/j.pain.2011.02.052. Epub 2011 Apr 1.
Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016.
Staci M Peron, Ph.D.
National Cancer Institute (NCI)
252 participants (actual enrollment reported by the registry).
First Submitted
July 11, 2012
First Posted
July 13, 2012
Study Start
August 6, 2012
Actual (reported)Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Contact the study team to confirm eligibility.
Engel JM, Jensen MP, Ciol MA, Bolen GM. The development and preliminary validation of the pediatric survey of pain attitudes. Am J Phys Med Rehabil. 2012 Feb;91(2):114-21. doi: 10.1097/PHM.0b013e318238a074.
Primary Completion
June 28, 2023
Actual (reported)Study Completion
June 28, 2023
Actual (reported)Last Updated
June 21, 2024
Record last verified: 2024-06
.All IPD recorded in the medical record will be shared with intramural investigators upon request.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: